No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Notice Selected | The sales for new car manufacturers in February are out! Xiaopeng has exceeded 0.03 million units for four consecutive months; ZTE's net income in 2024 has decreased by 9.7% year-on-year.
In February, Ideal delivered 26,263 vehicles, a year-on-year increase of 29.7%; NIO delivered 13,192 new vehicles in February, a year-on-year increase of 62.2%.
BAIYUNSHAN PH (00874.HK) plans to hold a Board of Directors meeting on March 13 to approve the annual performance.
Glory Financial announced on February 28 that BAIYUNSHAN PH (00874.HK) has determined that the Board of Directors will hold a meeting on March 13, 2025 (Thursday) to review and approve the audited financial performance of the company and its subsidiaries for the twelve months ending December 31, 2024, and to address other matters (if any).
BAIYUNSHAN PH: Date of Board Meeting
BAIYUNSHAN PH (00874): Guangzhou Pharmaceutical sells the second additional Assets with a consideration of 0.583 billion yuan.
BAIYUNSHAN PH (00874) announced that on February 28, 2025, Guangzhou Pharmaceutical and Xingzheng Asset Management, based on the underlying assets...
BAIYUNSHAN PH (00874.HK) subsidiary sells accounts receivable.
On February 28, Gelonghui reported that BAIYUNSHAN PH (00874.HK) announced that on February 28, 2025, Guangzhou Medicine (a non-wholly-owned subsidiary of the company) signed a "Newly Added Base Asset Delivery Confirmation Letter" with Xingzheng Asset Management according to the basic asset sale agreement (Phase IV), confirming the sale of the second batch of newly added base assets to Xingzheng Asset Management, and received a purchase payment of 0.583 billion yuan.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
